Involvement of patients and consumers in the Agency's activities
Patients and consumers are the end-users of the medicines that the European Medicines Agency evaluates, so they are key stakeholders with specific knowledge and expertise to offer the Agency.
The Agency is committed to maintaining a strong working relationship with patients and consumers and is interacting with a growing number of patients’ and consumers’ organisations.
See more information on the Agency's work with patients and consumers.
Searching for medicines by therapeutic area
It is possible to browse for a medicine by therapeutic area. The Agency categorises each medicine it assesses using a taxonomy which can be easily browsed. Go to European public assessment reports (EPARs) and use the 'browse by therapeutic area' tab.
Beware of falsified medicines!
Falsified medicines are fake medicines that may enter the supply chain illegally. Be careful about the way you buy medicines. Find more information on falsified medicines.
Search for herbal medicines
The Agency is responsible for supporting the harmonisation of herbal medicinal products in Europe. Search for herbal medicines assessed by the Agency's Committee on Herbal Medicinal Products.
News for patients and carers
The European Medicines Agency's (EMA) Pharmacovigilance Risk Assessment Committee (PRAC) gave recommendations on three safety referrals at its March 2014 meeting. ... Read more
PRAC recommends product information of zolpidem be updated with new advice to minimise the risk of next-morning impaired driving ability and mental alertness
The European Medicines Agency’s Pharmacovigilance Risk Assessment Committee (PRAC) has completed a review of zolpidem-containing medicines, used for the short-term treatment of insomnia (inability to sleep). ... Read more
The European Medicines Agency’s Pharmacovigilance Risk Assessment Committee (PRAC) has completed a review of domperidone-containing medicines and has recommended changes to their use throughout the European Union (EU), including using these medicines only to relieve symptoms of nausea and vomiting, restricting the dose and adjusting doses carefully by weight where it is licensed in children. ... Read more
The EMA’s Pharmacovigilance Risk Assessment Committee (PRAC) has re-examined diacerein-containing medicines and is recommending that they remain available but with restrictions to manage the risks of severe diarrhoea and effects on the liver. ... Read more
Update - EMA's Executive Director Guido Rasi together with Paola Testori Coggi from the European Commission and Luca Pani from AIFA receive European Rare Disease Leadership Award 2014. ... Read more
- See all News for patients and carers
Events of interest
European Medicines Agency Human Scientific Committees' Working Party with Patients’ and Consumers’ Organisations (PCWP) and Healthcare Professionals Working Party (HCPWP) joint meeting - Workshop on regulatory and methodological standards to improve benefit/risk evaluation of medicines
This is a joint Workshop with representatives from patients', consumers' and healthcare professionals' organisations. The workshop will provide an overview of current international benefit-risk initiatives as well as on the outcomes of recent EMA/CHMP benefit-risk projects. The on-going initiatives to capture patient values and preferences in benefit-risk and to translate benefit-risk regulatory decisions into product information will also be presented. Participants will have an opportunity to discuss, through practical examples, how benefit-risk models in general could support healthcare professionals and patients in the therapeutic decision-making process. Registration by invitation only. ... Read more
European Medicines Agency / health-technology-assessment-body workshop on parallel scientific advice in drug development
The European Medicines Agency (EMA) is holding a one-day workshop on parallel scientific advice with health-technology-assessment (HTA) bodies on evidence-generation in human-medicine development. The workshop is a joint undertaking of the EMA, HTA bodies and developers. Registration closed. Places limited. ... Read more
Consultation meeting with stakeholders: Request from the European Commission for advice on the impact on public and animal health of the use of antibiotics in animals
The European Medicines Agency having received a request from the European Commission for scientific advice on the impact on public health and animal health of the use of antibiotics in animals. In the interest of transparency, and in order to provide stakeholders with the opportunity to input information, data and/ or views, the EMA is organising a consultation exercise as a part of the preparation of the advice. Registration by invitation only. Places limited. ... Read more
Patients’ and Consumers’ Working Party (PCWP) and Healthcare Professionals' Working Party (HCPWP) joint meeting
This is a joint meeting with the representatives from patients’, consumers’ and healthcare professionals’ organisations. The election of the PCWP and HPWP co-chairs is taking place during the morning. The participants are also discussing issues in relation to their general involvement in the Agency’s activities, giving particular focus to product shortages, feedback from the ‘conflicts-of-interests workshop’ and the Agency's benefit / risk project. Registration by invitation only. ... Read more
28/11/2013 - 29/11/2013
The TOPRA Annual Regulatory Review is a favorite with European regulatory professionals as it is the key year-end event that allows a wide range of interested parties to reflect on issues affecting the European Medicines Agency in the year gone by and consider the challenges ahead for national agencies and other stakeholders. ... Read more
- See all Events of interest